|
|
||||||||
PROTEIN AND VESICLE TRAFFICKING, CYTOSKELETON
1Laboratory of Kidney and Electrolyte Metabolism and 2Proteomics Core Facility, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland; and 3Universidad Autónoma de Madrid and Consejo Superior de Investigaciones Científicas, Cantoblanco, Madrid, Spain
Submitted 26 December 2007 ; accepted in final form 2 July 2008
| ABSTRACT |
|---|
|
|
|---|
aquaporin-2; vasopressin; membrane rafts; mass spectrometry; proteomics
Membrane rafts are defined as small (10–200 nm), highly dynamic, heterogeneous, sterol- and sphingolipid-enriched membrane microdomains (45, 49). They undergo rapid assembly and disassembly and are believed to cluster together to function as a platform for membrane signaling and trafficking. Certain types of proteins, including GPI-anchored proteins, heterotrimeric G protein
-subunits, dually acylated proteins such as Src tyrosine kinases, palmitoylated and myristoylated proteins such as flotillins, cholesterol-binding proteins such as caveolins, and phospholipid-binding proteins such as annexins, have been reported to segregate into membrane rafts (49). Such proteins can be identified in detergent-resistant membrane (DRM) fractions, because raftlike domains are not fully solubilized by nonionic detergents such as Triton X-100 at low temperature and remain buoyant in density gradient centrifugation. An important goal in a systems-level analysis of AQP2 regulation is identification of proteins in collecting duct cells, including membrane raft proteins, which have the potential to play roles in transport regulation. A key tool in this endeavor is tandem mass spectrometry [LC-MS/MS, i.e., liquid chromatography (LC)-mass spectrometry (MS)], which has the potential to identify and quantify large numbers of proteins in biochemically prepared samples. Previously, we used LC-MS/MS to identify proteins in AQP2-containing vesicles (1) and in apical and basolateral plasma membranes isolated via surface biotinylation (59).
DRMs prepared with nonionic detergent extraction and discontinuous sucrose gradient centrifugation are not generally identical to membrane rafts because proteins may be lost or added during purification of DRMs (4). Nevertheless, isolation of DRMs can enrich proteins normally present in membrane rafts that may otherwise be difficult to detect by LC-MS/MS of whole membrane fractions. As a step to understand apical trafficking of AQP2, we have used LC-MS/MS to analyze the proteome of DRMs isolated from AQP2-expressing IMCD cells.
| MATERIALS AND METHODS |
|---|
|
|
|---|
IMCD cell suspension.
Detailed procedures for preparation of IMCD cell suspensions have been described previously (8). Briefly, 20 adult rats (200–250 g body wt) were treated with furosemide (5 mg/rat ip for 20 min), which dissipates the medullary osmolality, thereby preventing osmotic shock to the cells on isolation of the inner medullas (52). The animals were killed by decapitation, and both inner medullas were excised from the kidneys. The inner medullas were minced into
1-mm cubes and digested with 2 mg/ml hyaluronidase and 3 mg/ml collagenase B in 4 ml of isolation solution [250 mM sucrose and 10 mM Tris (pH 7.4)] at 37°C for 90 min. The samples were subjected to centrifugation at 60 g for 20 s to gently sediment the heavier IMCD segments from the non-IMCD components of the inner medulla (loops of Henle, interstitial cells, vasa recta, and capillaries). The sedimented IMCD segments were washed three times in 4 ml of ice-cold isolation solution and centrifuged as described above. Microscopic examination was carried out to confirm that the resulting suspensions contain mostly IMCD cells (>90% of total cells). The IMCD cells were finally suspended in 2 ml of ice-cold HEPES-buffered saline solution (in mM: 162.5 NaCl, 25 HEPES, 4 KCl, 2.5 Na2HPO4, 1.2 MgSO4, 2 CaCl2, and 5.5 glucose) before treatment with the vasopressin analog [deamino-Cys1,D-Arg8]vasopressin (dDAVP).
DRM preparation. A modification of the methods of Brown and Rose (5) and Foster et al. (15), which uses the nonionic detergent Triton X-100 and discontinuous sucrose gradient centrifugation, was used for preparation of IMCD DRMs. All the procedures described below were carried out at 4°C. TNE buffer (in mM: 25 Tris, 150 NaCl, and 5 EDTA) was supplied with protease inhibitor cocktail (catalog no. 11836153001, Roche Diagnostics, Indianapolis, IN) at one tablet per 10 ml of solution. For preparation of IMCD DRMs, IMCD cells were pelleted by brief centrifugation at 60 g. HEPES-buffered saline solution was removed, and the IMCD cell pellet was solubilized in 2 ml of 1% Triton X-100 in TNE buffer for 3 h with rotary motion. An equal volume of 80% (wt/vol) sucrose in TNE buffer was then added to the solubilized IMCD to make a final 40% sucrose solution, which was placed at the bottom of a centrifuge tube (catalog no. 331372, Beckman Coulter, Fullerton, CA). On the top of the 40% sucrose solution, 4 ml of 35% sucrose solution in TNE buffer were overlaid, followed by 4 ml of 5% sucrose solution in TNE solution. Ultracentrifugation was carried out using a swing-bucket rotor (model SW41 Ti, Beckman Coulter) at 39,000 rpm (188,000 g) for 20 h. Between 10 and 17 fractions were collected from the top to the bottom of the centrifuge tube and stored at –20°C.
dDAVP treatment. For quantitative proteomic comparison between vehicle- and dDAVP-treated IMCD cells, an IMCD cell suspension obtained from 20 rats was divided into two parts, 1 ml each for vehicle and dDAVP treatment. The IMCD cell suspensions were warmed to 37°C for 30 min, and 1 ml of prewarmed HEPES-buffered saline solution containing 0 or 2 nM dDAVP (1 nM final dDAVP concentration) was added to the suspensions. The IMCD cell suspensions were incubated for 20 min and then stored on ice, moved to a cold (4°C) room, and used for the membrane raft preparation. The above-described experiment was repeated three times to obtain enough protein from 60 rats for quantitative LC-MS/MS. Samples from each experiment were analyzed and stored separately. They were pooled only before LC-MS/MS protein identification.
Immunoblotting. Immunoblotting was carried out as previously described (12). After solubilization in Laemmli's reagent, 10–15 µl of each fraction were resolved by SDS-PAGE on a 4–15% gradient polyacrylamide minigel and transferred electrophoretically onto a nitrocellulose membrane. The membrane was blocked with 5% nonfat dry milk in blot washing buffer (in mM: 42 Na2HPO4, 8 NaH2PO4, and 150 NaCl) containing 0.05% Tween 20 (pH 7.5), washed with the blot washing buffer, and then incubated with a primary antibody diluted in a blocking buffer (catalog no. 927-40000, Li-Cor Biotechnology, Lincoln, NE) overnight at room temperature. After it was washed, the membrane was incubated with species-specific secondary antibody conjugated to fluorescent IRDye diluted in the blocking buffer. The membrane was washed, and antibody binding was visualized using the Odyssey Infrared Imaging System (Li-Cor Biotechnology).
The antibody against the Na+- and Cl–-dependent taurine transporter (TauT) was a gift from Russell Chesney (University of Tennessee Health Science Center, Memphis, TN). The antibodies against myosin IIA and IIB were provided by Robert S. Adelstein (NHLBI) (44). The antiserum against myosin VB was provided by John A. Hammer (NHLBI). The antibody against phosphorylated AQP2 at serine 256 has been previously characterized (41). The antibodies against AQP1 (55), AQP2 (1), MAL/vesicular integral protein 17 (VIP17) (30), Na+-K+-2Cl– cotransporter (NKCC2) (26), SNAP23 (21), UT-A1 (40), and vesicle-associated membrane protein (VAMP)-2 (28) were raised in our laboratories. The rabbit polyclonal antibody against MAL-2 was raised against a synthetic peptide, NPAVSFPAPRITLPAG, conjugated to keyhole limpet hemocyanin. Similarly, the rabbit polyclonal antibodies against Na+-K+-ATPase
1-subunit were raised against keyhole limpet hemocyanin-conjugated synthetic peptides against CDEVRKLIIRRRPGGWVEKETYY. The commercial antibodies against caveolin-1 (catalog no. 610406), caveolin-2 (catalog no. 610684), E-cadherin (catalog no. 610181), flotillin-1 (catalog no. 610820), flotillin-2 (catalog no. 610384), Rab11 (catalog no. 610656), and RalA (catalog no. 610221) were obtained from BD Transduction Laboratories (San Jose, CA); antibodies against annexin A2 (catalog no. sc-1924), annexin A4 (catalo6g no. sc-1930), G
i3 (catalog no. sc-262), G
s (catalog no. sc-823), Gβ1 (catalog no. sc-379), Gβ2 (catalog no. sc-380), Rab5b (catalog no. sc-598), and Rap1 (catalog no. sc-65) from Santa Cruz Biotechnology (Santa Cruz, CA); antibodies against β-actin (catalog no. 4967) and myosin light chain 2 (catalog no. 3672) from Cell Signaling Technology (Beverly, MA); antibodies against myosin IC (catalog no. M3567) and ezrin (catalog no. E1281) from Sigma-Aldrich (St. Louis, MO); antibodies against calnexin (catalog no. SPA-860), Sec6 (catalog no. VAM-SV021), and Sec8 (catalog no. VAM-SV016) from Stressgen Bioreagents (Ann Arbor, MI); antibody against Src (catalog no. 05-184) from Millipore (Charlottesville, VA); antibody against syntaxin 7 (catalog no. 110 072) from Synaptic Systems (Goettingen, Germany); and species-specific secondary antibodies from Rockland Immunochemicals (Gilbertsville, PA).
Immunofluorescence confocal microscopy. Techniques for indirect immunofluorescence staining of kidney sections were described previously (59). Confocal fluorescence images were obtained using a Zeiss LSM 510 microscope and software (Carl Zeiss MicroImaging, Thornwood, NY) at the Light Microscopic Facility in the National Heart, Lung, and Blood Institute.
Preparation of proteins for mass spectrometric identification.
Proteins in the membrane raft fraction (fraction 5) were concentrated using 10,000-Da cutoff Amicon Ultra-4 Centrifugal Filter Devices (Millipore, Bedford, MA) and separated on a 4–15% gradient SDS-PAGE minigel (Bio-Rad Life Science, Hercules, CA). The gel was stained with Coomassie blue (GelCode, Pierce Biotechnology) for visualization of the proteins, and the entire sample lane was cut into 16 sequential
2-mm-thick slices. Proteins in each gel slice were destained, reduced, alkylated, and digested with trypsin using a previously described protocol (46) before LC-MS/MS protein identification.
LC-MS/MS protein identification and analysis. Tryptic peptides extracted from each gel slice were injected into a reverse-phase LC column (PicoFrit, Biobasic C18, New Objective, Woodburn, MA) to stratify sample proteins before delivery to an LTQ tandem mass spectrometer (MS/MS, Thermo Electron, San Jose, CA) via a nanoelectrospray ion source. The spectra with a total ion current >10,000 were used to search for matches to peptides in a concatenated RefSeq database using Bioworks software (version 3.1, Thermo Electron) based on the Sequest algorithm. The concatenated RefSeq database is composed of forward protein sequences (24,096 entries) and reverse protein sequences (24,096 entries) derived from the National Center for Biotechnology Information on 6 June 2006 using in-house software. The search parameters included 1) precursor ion mass tolerance <2 atomic mass units (amu), 2) fragment ion mass tolerance <1 amu, 3) as many as three missed tryptic cleavages, and 4) amino acid modifications as follows: cysteine carboxyamidomethylation (plus 57.05 amu) and methionine oxidation (plus 15.99 amu).
For protein identifications, in-house software was used to filter the matched peptide sequences using the following initial settings: 1) ranks of the primary scores <10, 2) ranks of the cross-correlation (Xcorr) scores = 1, 3) Xcorr scores >1.3, 1.8, and 2.3 for charged states 1, 2, and 3 peptide ions, respectively, and 4) uniqueness scores of matches >0.1. The software then used probability-based target-decoy analysis to minimize false-positive protein identification (2). Peptide matches to the reverse sequences were considered random and were used to calculate a random peptide match rate, which was defined as the number of peptide matches to the reverse sequences divided by the total number of peptide matches. The rate of false-positive peptide matches to the forward sequences was assumed to be the same as the rate of random peptide matches. The software then elevated the Xcorr score of each charge state by 0.1 units and calculated a new false-positive peptide match rate until the false-positive peptide match rate reached 2.5%. The false-positive protein identification rate was calculated as follows: [false-positive peptide match rate/(1 – random peptide match rate)]n, where n is the number of peptides identified for that protein.
Data repository. Raw mass spectrometric raw data are deposited in the Tranche repository to facilitate data sharing and validation. To retrieve the raw data, run a JAVA program at this link, http://www.proteomecommons.org/dev/dfs/GetFileTool.jnlp, and provide the hash, Qk/MRVLDN73LgtKO56wrmZbvA4ZyCe4LUmqr/WfELDDoEIgi4uAQ/mGfjgx8exsLzKkqDabsFsrhQRoJwiDUyfxtHSQAAAAAAAAtTg==.
Quantification and statistics. Label-free quantitative analysis of protein abundance was performed using QUOIL software (58), which calculated the ratios of the areas of the reconstructed peptide LC elution profiles from two samples. The peptide mass tolerance was set to 1.1 Da. The minimal signal-to-noise threshold was set at 1.5-fold. Noise was subtracted from the calculation of relative peptide abundance. To determine whether a protein was more abundant in one sample than in another other, we used the two-tailed Student's t-test to test whether the mean base 2 logarithmic (log2) values of the ratios of the areas of all peptide elution profiles of the same protein are different from zero. Proteins that passed the t-test with positive mean log2 values were considered more abundant in one sample, whereas proteins that passed the t-test with negative mean log2 values were considered more abundant in the other sample. Proteins that did not pass the t-test were considered indeterminant with regard to their relative abundance in samples. It is likely that they were relatively abundant in both samples.
The IMCD accounts for only a small fraction of the whole kidney, and DRM proteins are only a small fraction of IMCD proteins. Therefore, a large number of animals were needed to obtain sufficient DRM protein for mass spectrometry. To initially characterize the DRM fraction, we used 20 rats. To compare proteomes of vehicle- and dDAVP-treated DRMs, we pooled 3 DRM preparations from 60 rats (see above). The use of so many rats per sample has the advantage of buffering the effect of biological variability. Finally, to account for analytic variation by the QUOIL software, we validated the quantification results by immunoblotting.
Bioinformatics and statistics.
Protein information was retrieved from the Universal Protein Resource (UniProt; http://www.expasy.uniprot.org) using the Batch Retrieval function from the Protein Information Resource (PIR) website (http://pir.georgetown.edu). Cellular component gene ontology (GO) terms were extracted directly from the National Center for Biotechnology Information protein database using in-house software. A
2 test was performed to determine whether one protein population displayed a given protein characteristic (i.e., a GO term) more frequently than the other protein population. The
2 test was done using InStat software (version 3.00 for Windows, GraphPad Software, San Diego, CA).
| RESULTS |
|---|
|
|
|---|
1-subunit, and TauT. The vasopressin-regulated water channel AQP2 was found in DRM and non-DRM fractions in approximately equal amounts. The DRM preparation shown in Fig. 1 was used for LC-MS/MS proteomic analysis.
|
2.5% (see MATERIALS AND METHODS). Table 1 shows the computational assessment of the protein identifications from the DRM and non-DRM fractions. Four hundred eleven proteins in the DRM fraction were identified by a single peptide match with a predicted false-positive rate of 2.6%. The predicted false-positive protein identification rates decrease exponentially as the number of peptides identified for particular proteins increases. Four hundred three proteins were identified in the DRM fraction on the basis of two or more peptides with false-positive rates <0.1%. Overall, a total of 814 proteins were identified in the DRM fraction and 1,212 proteins were identified in the non-DRM fraction with the indicated filters (Table 1). [See supplemental Tables S1 (fraction 5, DRM fraction) and S2 (fraction 14, non-DRM fraction) for a list of these protein identifications with their identified peptide sequences and associated statistical scores. Also, see supplemental Figs. S2 and S3 for spectra of single-peptide identifications, along with their observed precursor mass-to-charge ratios (m/z).]
|
|
-subunits, Lyn tyrosine kinase, flotillins, Tamm-Horsfall protein, and Src tyrosine kinase, indicating enrichment of membrane rafts in the IMCD DRM fraction. AQP2 was identified by LC-MS/MS in the DRM and non-DRM fractions. The vasopressin-regulated urea transporter UT-A1 was identified in the DRM fractions.
|
|
2 test), whereas the non-DRM list had more proteins that were associated with cytoplasm (P < 0.0001) and cytosol (P < 0.0001).
|
|
|
i2, G
i3, and two Src-family tyrosine kinases (Lyn and Src). The singly myristoylated cytochrome b5 reductase was identified in the indeterminable group. Protein palmitoylation often promotes raft association (4). The identification of palmitoylated (but not myristoylated) proteins G
s, G
q, SNAP23, and anion-exchange protein 1 (AE1, an integral membrane protein) in the IMCD DRM fraction is consistent with this type of membrane raft-targeting mechanism. Proteins with prenylation are often excluded from membrane rafts (4). However, we found five prenylated small GTP-binding proteins (RalA, RalB, RAP-1A, Rac1, and Rab11) in the IMCD DRM fraction. The SH2 domain can bind phospholipids in addition to phosphorylated tyrosine (16). Two SH2 domain-containing proteins, Lyn and Src tyrosine kinases, were identified in the IMCD DRM fraction. Proteins containing phospholipid-binding PH or C2 domains for membrane association (20) were identified primarily in the non-DRM fraction and the indeterminable protein group. Most annexins associate with membranes via Ca2+-dependent binding to negatively charged phospholipids (16). Annexins were identified chiefly in the non-DRM and the indeterminable protein group.
|
|
-subunits, and small GTP-binding proteins, were in the common proteome list. In addition, three soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins, namely, syntaxin 7, syntaxin 13, and VAMP2, were also common to the DRM fraction and the AQP2-containing vesicles. The list also includes adaptor protein (AP-2) complex and four members of the transmembrane emp24 domain-containing protein family.
|
Figure 9A shows the purity and viability of the IMCD cell suspension. The IMCD cell suspension was 6.2-fold enriched with the IMCD marker protein AQP2 and 6.0-fold depleted of the non-IMCD marker protein AQP1 compared with the non-IMCD cell suspension prepared from 20 rats. We estimate that 86% of the total protein in the IMCD-enriched cell suspension was actually from IMCD cells (19). When exposed to 1 nM dDAVP for 20 min, the IMCD cell suspension responded with a 4.0-fold increase in phosphorylation at serine 256 of the AQP2 COOH-terminal tail compared with the vehicle-treated cells, consistent with previous observations (7). In contrast, the amount of total AQP2 was unchanged in the dDAVP-treated cells relative to the vehicle-treated cells. Having established the purity and viability of the IMCD cell suspension, Fig. 9B shows a comparison of the DRM preparations from the vehicle- and dDAVP-treated IMCD cells from the perspective of several of the DRM proteins identified above. Fraction 5 has the highest abundance of MAL/VIP17 in vehicle- and dDAVP-treated IMCD cells, defining the location of the DRMs. The immunoblot in Fig. 9B also shows that AQP2 is present in DRM and non-DRM fractions in these preparations and that the distribution of AQP2 is similar between dDAVP- and vehicle-treated IMCD cells. Similar results were observed in two other experiments (see supplemental Fig. S5). The DRM fractions (fractions 4–6) of vehicle- and dDAVP-treated IMCD cells from the three above-described experiments (60 rats; Fig. 9, also see supplemental Fig. S5) were pooled to obtain sufficient amounts of DRM protein for label-free quantitative mass spectrometric analysis. On average, the three IMCD cell suspensions contained
85.0% IMCD cell protein and responded to 1 nM dDAVP with a 3.1-fold increase in AQP2 phosphorylation at serine 256.
|
-actin, keratin 75, AQP1, Rab7, annexin A2, and keratin 14 showed small increases, whereas β-actin, prohibitin, keratin 10, and annexin A1 showed small decreases, in the IMCD DRM fractions after dDAVP treatment. Among the 60 proteins that did not show significant changes, 16 were previously identified in AQP2-containing intracellular vesicles (Table 3): AQP2, ATP synthase mitochondrial F1 complex
-subunit, ATP synthase mitochondrial F1 complex β-subunit, ATPase V1 complex B2 subunit, ATPase H+-transporting V0 complex subunit d1, ATPase Na+-K+-transporting
1-subunit, B-cell receptor-associated protein 37, crystallin
B, cytochrome c oxidase subunit IV isoform 1, cytochrome c oxidase subunit Va, heat shock-related 70-kDa protein 2, keratin 4, keratin 8, VAMP2, syntaxin 7, and "similar to SPFH domain family member 2."
|
|
10%) decrease in the ratio of the amount of AQP2 in fraction 5 to that in fractions 5 + 10 (Fig. 10B). Treatment with dDAVP significantly increased AQP2 phosphorylation at serine 256 in both fractions (Fig. 10C). The ratio of phosphorylated AQP2 at serine 256 to total AQP2 was significantly higher in fraction 5 than in fraction 10 before and after dDAVP treatment (Fig. 10C). Treatment with dDAVP did not change phosphorylation of AQP2 at serine 261 in these fractions (Fig. 10D). There was more phosphorylated AQP2 at serine 264 in fraction 5 than in fraction 10 before dDAVP treatment (Fig. 10E). Phosphorylated AQP2 at serine 264 appeared to increase in response to dDAVP, although the change was not significant.
|
1, and Rab5b. Equal volumes of protein sample from fractions 5 and 10 were chosen to represent the IMCD DRM and non-DRM fractions, respectively. None of these proteins showed significant changes in their association with the IMCD DRM or non-DRM fractions in response to 1 nM dDAVP.
|
| DISCUSSION |
|---|
|
|
|---|
Label-free quantitative LC-MS/MS analysis using in-house quantification software (QUOIL) allowed statistical classification of identified proteins into three groups: those that were distinctly in the DRM fraction, those that were distinctly in the non-DRM fraction, and an "indeterminable" group that may be in both fractions. Probability-based target-decoy analysis was used to maintain the false-positive protein identification rate at <2.6% in single-peptide identifications and at much lower levels in multiple-peptide identification. Immunoblotting confirmed the QUOIL-based quantification results of 29 proteins that were identified by LC-MS/MS (Fig. 4). In addition to classical raft-associated proteins (GPI anchored and acylated), 58 integral membrane proteins were identified in our IMCD DRM fractions. These DRM-associated integral membrane proteins differed in their physical properties from those found in the IMCD cells, in that they were smaller and more hydrophobic on average (Fig. 8).
Immunofluorescence labeling of IMCDs with use of antibodies to classic raft marker proteins that were found in our proteomic analysis revealed that the raftlike domains in the cells are heterogeneous. In particular, MAL2 showed a predominant labeling of the apical region of the cells, RalA showed a predominant labeling of the basolateral region, caveolin-2 showed a punctate labeling distributed throughout the cells consistent with the intracellular presence of caveosomes, and flotillin-1 showed discrete labeling of large intracellular structures in the cells. Flotillin-1 defines an endosomal fraction that does not colocalize with clathrin and caveolin-1 in the mammalian cell line COS-7 (17). In summary, the confocal localization studies are consistent with marked heterogeneity of the DRM fraction. Thus proteins identified in our proteomic analysis of IMCD DRMs are not necessarily adjacent to one another in a single raftlike structure.
Comparison of the IMCD DRM proteins identified in the present study and proteins identified in other IMCD membrane domains in our previous studies revealed certain classes of proteins in common. In particular, the joint lists (Table 3) reveal consistent identification of proteins associated with the actin cytoskeleton, including certain types of nonmuscle myosins and molecular motors responsible for moving and organizing actin filaments (F-actin) in the cells. In contrast, there did not appear to be enrichment of microtubule-associated proteins or microtubule-based molecular motors. A role for actin in the regulation of AQP2 trafficking by vasopressin has been demonstrated previously (43, 56). The general conclusion from these prior studies is that movement of AQP2-containing vesicles to the apical plasma membrane depends in part on F-actin depolymerization in the subapical cortex of the cells. In addition, we previously found that the ability of vasopressin to increase osmotic water permeability in isolated perfused IMCD segments is markedly impaired by inhibitors of actin polymerization (latrunculin B) or depolymerization (jasplakinolide) (7), as well as inhibitors of myosin light chain kinase (ML-7 and ML-9) (7), inhibitors of calmodulin (W7 and trifluoperazine) (10), and inhibitors of nonmuscle conventional myosins (blebbistatin) (9). Unconventional myosins such as myosin I have been proposed to play a role in organizing raftlike domains through a role in maintaining so-called membrane "skeletons" beneath the plasma membrane (34).
We also found a number of membrane-trafficking proteins in both the protein list for DRMs and the protein list for intracellular AQP2-containing vesicles (Table 3). These proteins include four transmembrane emp24 domain-containing proteins, which are thought to be involved in the early secretory pathway (35), and a small GTP-binding protein (Rab11) involved in endosome recycling (27), a small GTP-binding protein (RalB) associated with exocyst functions (57), and a small GTP-binding protein (Rac1) associated with regulation of the actin cytoskeleton (50). In addition, SNARE proteins, specifically, syntaxin 13 (associated with recycling endosomes) (48) and syntaxin 7 (associated with late endosomes) (32), were among the proteins common to both lists. Thus the proteomic analyses of the DRM fractions and AQP2-containing vesicles revealed several proteins potentially involved in vasopressin signaling and AQP2 trafficking and are consistent with a critical role for endosomal compartments.
An important feature of the IMCD DRM proteome determined in the present study was the predominance of GTP-binding proteins, both small GTP-binding proteins and heterotrimeric G protein
-subunits. The small GTP-binding proteins included those associated with endosomal trafficking (Rab proteins), actin dynamics (Rho-like proteins), exocyst (Ral) proteins, and regulation of the MAP kinase cascade (Ras and Rap proteins). Heterotrimeric G proteins are, of course, involved in signaling, although recent evidence has led to the proposal that these proteins, when present on intracellular vesicles, can play a role in the regulation of membrane trafficking (60). The small and the heterotrimeric GTP-binding proteins obviously have potential roles in AQP2 regulation.
AQP2 is known to have a distinct intracellular localization in the kidney collecting duct cells characterized by diffuse labeling with anti-AQP2 antibodies throughout the cytoplasm (53). In our recent proteomics study of AQP2-bearing vesicles immunoisolated from the IMCD cells, we identified small GTP-binding proteins, Rab4/5, Rab11/25, and Rab7, associated with early endosomes, recycling endosomes, and late endosomes, respectively (1). However, we could not identify Rab3, a marker for secretory vesicles, in AQP2-bearing vesicles by immunoblotting and LC-MS/MS methods. These results suggested trafficking of AQP2 to the plasma membrane via endosomes, rather than secretory vesicles (1, 53). Hypothetically, vasopressin may regulate AQP2 trafficking or activation, in part through membrane raft association. Recent work demonstrated a direct binding interaction between AQP2 and the membrane raft protein MAL/VIP17 (25). We tested whether exposure of freshly isolated rat IMCD segments to vasopressin altered the distribution of AQP2 between the DRMs isolated in a manner similar to those used for proteomic analysis and the non-DRM membrane fraction of the IMCD cells. However, vasopressin did not result in a significant change in the AQP2 content of DRMs (Fig. 10). There was a significant 10% decrease in the ratio of AQP2 in fraction 5 to AQP2 in fractions 5 + 10. However, the small magnitude of this change raises concerns about its physiological relevance. Given the heterogeneity of the structures that contribute to biochemically isolated DRMs, it seems possible that a vasopressin response was absent, simply because changes in some raftlike subfractions may have been diluted by the absence of changes in other raftlike subfractions. Interestingly, we also found that the fraction of AQP2 phosphorylated at serine 256 is greater in DRM than in non-DRM fractions, raising the possibility that the kinase responsible for phosphorylation may be associated with membrane rafts or that the phosphatase responsible for dephosphorylation may be associated with nonraft membranes. Alternatively, the serine 256 phosphorylated form of AQP2 may be segregated into raftlike domains, or the nonphosphorylated form may be selectively segregated into nonraft domains.
A possible role for MAL/VIP17 in the raft localization of AQP2 requires further study. MAL/VIP17 is involved in the delivery of some apical membrane proteins (6), as well as clathrin-mediated endocytosis in Madin-Darby canine kidney cells (31). Enhancing apical delivery and/or decreasing apical endocytosis will increase apical AQP2 abundance. There is evidence consistent with a vasopressin-induced decrease in clathrin-mediated endocytosis of water channels in collecting ducts (38, 39). The MAL-related proteins MAL2 and Myadm (Table 3) were also identified in the present study. Their role in AQP2 regulation has not been investigated. Marazuela and Alonso (29) proposed that MAL2 is involved in transcytosis. Given that a large fraction of AQP2 is located basolaterally, in addition to apically (11, 24, 36), it seems possible that AQP2 undergoes transcytosis in the process of its targeting to the apical plasma membrane. For example, basolateral AQP2, possibly delivered via an exocyst-dependent mechanism, could undergo endocytosis in the basolateral plasma membrane via caveolae and move in raftlike caveosomes to fuse with the apical plasma membranes (1, 47).
With use of matrix-assisted laser desorption ionization/time-of-flight (MALDI-TOF) mass spectrometry (42) annexin 2 was previously identified as a binding partner of AQP2 in rat kidney inner medulla and was identified in AQP2-bearing vesicles in rat IMCD cells using LC-MS/MS (1). Recently, annexin 2 was shown to translocate from cytosol to membrane fractions in response to forskolin in cultured mouse collecting duct cells (54). This response was associated with a significant increase in the amount of annexin 2 in a membrane raftlike fraction. Our quantitative proteomic results showed a small increase in annexin 2 in IMCD DRMs in response to dDAVP (Table 5), consistent with the suggested role of annexin 2 in AQP2 trafficking.
It was interesting that quantification from label-free LC-MS/MS analysis and quantification by immunoblot analysis was concordant, although the LC-MS/MS approach generally gave lower ratios. The immunoblot analysis was quantified by near-infrared fluorescence (Li-Cor Odyssey Infrared Imaging System), which in our experience is highly linear over at least two orders of magnitude of signal intensity. Thus we suspect that the discrepancy in the quantification values is due to nonlinearity in the nonlabeling LC-MS/MS analysis. Such nonlinearity could conceivably arise from the background correction element of the QUOIL-based analysis. If background correction were consistently too large, the derived ratios between samples would be underestimated. Nevertheless, the high correlation with immunoblot-based quantification supports the validity of the LC-MS/MS quantification.
| GRANTS |
|---|
|
|
|---|
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
| REFERENCES |
|---|
|
|
|---|
2. Beausoleil SA, Villen J, Gerber SA, Rush J, Gygi SP. A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat Biotechnol 24: 1285–1292, 2006.[CrossRef][Web of Science][Medline]
3. Brown D, Roth J, Orci L. Lectin-gold cytochemistry reveals intercalated cell heterogeneity along rat kidney collecting ducts. Am J Physiol Cell Physiol 248: C348–C356, 1985.
4. Brown DA. Lipid rafts, detergent-resistant membranes, and raft targeting signals. Physiology (Bethesda) 21: 430–439, 2006.[CrossRef][Medline]
5. Brown DA, Rose JK. Sorting of GPI-anchored proteins to glycolipid-enriched membrane subdomains during transport to the apical cell surface. Cell 68: 533–544, 1992.[CrossRef][Web of Science][Medline]
6. Cheong KH, Zacchetti D, Schneeberger EE, Simons K. VIP17/MAL, a lipid raft-associated protein, is involved in apical transport in MDCK cells. Proc Natl Acad Sci USA 96: 6241–6248, 1999.
7. Chou CL, Christensen BM, Frische S, Vorum H, Desai RA, Hoffert JD, de Lanerolle P, Nielsen S, Knepper MA. Non-muscle myosin II and myosin light chain kinase are downstream targets for vasopressin signaling in the renal collecting duct. J Biol Chem 279: 49026–49035, 2004.
8. Chou CL, DiGiovanni SR, Luther A, Lolait SJ, Knepper MA. Oxytocin as an antidiuretic hormone. II. Role of V2 vasopressin receptor. Am J Physiol Renal Fluid Electrolyte Physiol 269: F78–F85, 1995.
9. Chou CL, Yu MJ, Kassai EM, Morris RG, Hoffert JD, Wall SM, Knepper MA. Roles of basolateral solute uptake via NKCC1 and of myosin II in vasopressin-induced cell swelling in inner medullary collecting duct. Am J Physiol Renal Physiol 295: F192–F201, 2008.
10. Chou CL, Yip KP, Michea L, Kador K, Ferraris JD, Wade JB, Knepper MA. Regulation of aquaporin-2 trafficking by vasopressin in the renal collecting duct. Roles of ryanodine-sensitive Ca2+ stores and calmodulin. J Biol Chem 275: 36839–36846, 2000.
11. Christensen BM, Wang W, Frokiaer J, Nielsen S. Axial heterogeneity in basolateral AQP2 localization in rat kidney: effect of vasopressin. Am J Physiol Renal Physiol 284: F701–F717, 2003.
12. DiGiovanni SR, Nielsen S, Christensen EI, Knepper MA. Regulation of collecting duct water channel expression by vasopressin in Brattleboro rat. Proc Natl Acad Sci USA 91: 8984–8988, 1994.
13. Fenton RA, Knepper MA. Urea and renal function in the 21st century: insights from knockout mice. J Am Soc Nephrol 18: 679–688, 2007.
14. Fenton RA, Moeller HB, Hoffert JD, Yu MJ, Nielsen S, Knepper MA. Acute regulation of aquaporin-2 phosphorylation at Ser-264 by vasopressin. Proc Natl Acad Sci USA 105: 3134–3139, 2008.
15. Foster LJ, De Hoog CL, Mann M. Unbiased quantitative proteomics of lipid rafts reveals high specificity for signaling factors. Proc Natl Acad Sci USA 100: 5813–5818, 2003.
16. Gerke V, Creutz CE, Moss SE. Annexins: linking Ca2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol 6: 449–461, 2005.[CrossRef][Web of Science][Medline]
17. Glebov OO, Bright NA, Nichols BJ. Flotillin-1 defines a clathrin-independent endocytic pathway in mammalian cells. Nat Cell Biol 8: 46–54, 2006.[CrossRef][Web of Science][Medline]
18. Hoffert JD, Nielsen J, Yu MJ, Pisitkun T, Schleicher SM, Nielsen S, Knepper MA. Dynamics of aquaporin-2 serine-261 phosphorylation in response to short-term vasopressin treatment in collecting duct. Am J Physiol Renal Physiol 292: F691–F700, 2007.
19. Hoffert JD, van Balkom BW, Chou CL, Knepper MA. Application of difference gel electrophoresis to the identification of inner medullary collecting duct proteins. Am J Physiol Renal Physiol 286: F170–F179, 2004.
20. Hurley JH, Misra S. Signaling and subcellular targeting by membrane-binding domains. Annu Rev Biophys Biomol Struct 29: 49–79, 2000.[CrossRef][Web of Science][Medline]
21. Inoue T, Nielsen S, Mandon B, Terris J, Kishore BK, Knepper MA. SNAP-23 in rat kidney: colocalization with aquaporin-2 in collecting duct vesicles. Am J Physiol Renal Physiol 275: F752–F760, 1998.
22. Ishikawa SE, Schrier RW. Pathophysiological roles of arginine vasopressin and aquaporin-2 in impaired water excretion. Clin Endocrinol (Oxf) 58: 1–17, 2003.[CrossRef][Medline]
23. Jahn R, Scheller RH. SNAREs—engines for membrane fusion. Nat Rev Mol Cell Biol 7: 631–643, 2006.[CrossRef][Web of Science][Medline]
24. Jeon US, Joo KW, Na KY, Kim YS, Lee JS, Kim J, Kim GH, Nielsen S, Knepper MA, Han JS.Oxytocin induces apical and basolateral redistribution of aquaporin-2 in rat kidney. Nephron Exp Nephrol 93: e36–e45, 2003.[CrossRef][Medline]
25. Kamsteeg EJ, Duffield AS, Konings IB, Spencer J, Pagel P, Deen PM, Caplan MJ. MAL decreases the internalization of the aquaporin-2 water channel. Proc Natl Acad Sci USA 104: 16696–16701, 2007.
26. Kim GH, Ecelbarger CA, Mitchell C, Packer RK, Wade JB, Knepper MA. Vasopressin increases Na-K-2Cl cotransporter expression in thick ascending limb of Henle's loop. Am J Physiol Renal Physiol 276: F96–F103, 1999.
27. Lapierre LA, Avant KM, Caldwell CM, Ham AJ, Hill S, Williams JA, Smolka AJ, Goldenring JR. Characterization of immunoisolated human gastric parietal cells tubulovesicles: identification of regulators of apical recycling. Am J Physiol Gastrointest Liver Physiol 292: G1249–G1262, 2007.
28. Mandon B, Chou CL, Nielsen S, Knepper MA. Syntaxin-4 is localized to the apical plasma membrane of rat renal collecting duct cells: possible role in aquaporin-2 trafficking. J Clin Invest 98: 906–913, 1996.[Web of Science][Medline]
29. Marazuela M, Alonso MA. Expression of MAL and MAL2, two elements of the protein machinery for raft-mediated transport, in normal and neoplastic human tissue. Histol Histopathol 19: 925–933, 2004.[Web of Science][Medline]
30. Martin-Belmonte F, Kremer L, Albar JP, Marazuela M, Alonso MA. Expression of the MAL gene in the thyroid: the MAL proteolipid, a component of glycolipid-enriched membranes, is apically distributed in thyroid follicles. Endocrinology 139: 2077–2084, 1998.
31. Martin-Belmonte F, Martinez-Menarguez JA, Aranda JF, Ballesta J, de Marco MC, Alonso MA. MAL regulates clathrin-mediated endocytosis at the apical surface of Madin-Darby canine kidney cells. J Cell Biol 163: 155–164, 2003.
32. Mullock BM, Smith CW, Ihrke G, Bright NA, Lindsay M, Parkinson EJ, Brooks DA, Parton RG, James DE, Luzio JP, Piper RC. Syntaxin 7 is localized to late endosome compartments, associates with Vamp 8, and is required for late endosome-lysosome fusion. Mol Biol Cell 11: 3137–3153, 2000.
33. Murata F, Tsuyama S, Suzuki S, Hamada H, Ozawa M, Muramatsu T. Distribution of glycoconjugates in the kidney studied by use of labeled lectins. J Histochem Cytochem 31: 139–144, 1983.[Web of Science][Medline]
34. Nebl T, Pestonjamasp KN, Leszyk JD, Crowley JL, Oh SW, Luna EJ. Proteomic analysis of a detergent-resistant membrane skeleton from neutrophil plasma membranes. J Biol Chem 277: 43399–43409, 2002.
35. Nickel W, Sohn K, Bunning C, Wieland FT. p23, a major COPI-vesicle membrane protein, constitutively cycles through the early secretory pathway. Proc Natl Acad Sci USA 94: 11393–11398, 1997.
36. Nielsen S, DiGiovanni SR, Christensen EI, Knepper MA, Harris HW. Cellular and subcellular immunolocalization of vasopressin-regulated water channel in rat kidney. Proc Natl Acad Sci USA 90: 11663–11667, 1993.
37. Nielsen S, Frokiaer J, Marples D, Kwon TH, Agre P, Knepper MA. Aquaporins in the kidney: from molecules to medicine. Physiol Rev 82: 205–244, 2002.
38. Nielsen S, Knepper MA. Vasopressin activates collecting duct urea transporters and water channels by distinct physical processes. Am J Physiol Renal Fluid Electrolyte Physiol 265: F204–F213, 1993.
39. Nielsen S, Muller J, Knepper MA. Vasopressin- and cAMP-induced changes in ultrastructure of isolated perfused inner medullary collecting ducts. Am J Physiol Renal Fluid Electrolyte Physiol 265: F225–F238, 1993.
40. Nielsen S, Terris J, Smith CP, Hediger MA, Ecelbarger CA, Knepper MA. Cellular and subcellular localization of the vasopressin-regulated urea transporter in rat kidney. Proc Natl Acad Sci USA 93: 5495–5500, 1996.
41. Nishimoto G, Zelenina M, Li D, Yasui M, Aperia A, Nielsen S, Nairn AC. Arginine vasopressin stimulates phosphorylation of aquaporin-2 in rat renal tissue. Am J Physiol Renal Physiol 276: F254–F259, 1999.
42. Noda Y, Horikawa S, Katayama Y, Sasaki S. Identification of a multiprotein "motor" complex binding to water channel aquaporin-2. Biochem Biophys Res Commun 330: 1041–1047, 2005.[CrossRef][Web of Science][Medline]
43. Noda Y, Sasaki S. Regulation of aquaporin-2 trafficking and its binding protein complex. Biochim Biophys Acta 1758: 1117–1125, 2006.[Medline]
44. Phillips CL, Yamakawa K, Adelstein RS. Cloning of the cDNA encoding human nonmuscle myosin heavy chain-B and analysis of human tissues with isoform-specific antibodies. J Muscle Res Cell Motil 16: 379–389, 1995.[CrossRef][Web of Science][Medline]
45. Pike LJ. Rafts defined: a report on the Keystone Symposium on Lipid Rafts and Cell Function. J Lipid Res 47: 1597–1598, 2006.
46. Pisitkun T, Shen RF, Knepper MA. Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci USA 101: 13368–13373, 2004.
47. Polishchuk R, Di Pentima A, Lippincott-Schwartz J. Delivery of raft-associated, GPI-anchored proteins to the apical surface of polarized MDCK cells by a transcytotic pathway. Nat Cell Biol 6: 297–307, 2004.[CrossRef][Web of Science][Medline]
48. Prekeris R, Klumperman J, Chen YA, Scheller RH. Syntaxin 13 mediates cycling of plasma membrane proteins via tubulovesicular recycling endosomes. J Cell Biol 143: 957–971, 1998.
49. Rajendran L, Simons K. Lipid rafts and membrane dynamics. J Cell Sci 118: 1099–1102, 2005.
50. Ridley AJ. Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking. Trends Cell Biol 16: 522–529, 2006.[CrossRef][Web of Science][Medline]
51. Sanchez-Pulido L, Martin-Belmonte F, Valencia A, Alonso MA. MARVEL: a conserved domain involved in membrane apposition events. Trends Biochem Sci 27: 599–601, 2002.[CrossRef][Web of Science][Medline]
52. Sands JM, Knepper MA. Urea permeability of mammalian inner medullary collecting duct system and papillary surface epithelium. J Clin Invest 79: 138–147, 1987.[Web of Science][Medline]
53. Tajika Y, Matsuzaki T, Suzuki T, Aoki T, Hagiwara H, Tanaka S, Kominami E, Takata K. Immunohistochemical characterization of the intracellular pool of water channel aquaporin-2 in the rat kidney. Anat Sci Int 77: 189–195, 2002.[CrossRef][Medline]
54. Tamma G, Procino G, Mola MG, Svelto M, Valenti G. Functional involvement of annexin-2 in cAMP induced AQP2 trafficking. Pflügers Arch 456: 729–736, 2008.[CrossRef][Web of Science][Medline]
55. Terris J, Ecelbarger CA, Nielsen S, Knepper MA. Long-term regulation of four renal aquaporins in rats. Am J Physiol Renal Fluid Electrolyte Physiol 271: F414–F422, 1996.
56. Valenti G, Procino G, Tamma G, Carmosino M, Svelto M. Aquaporin 2 trafficking. Endocrinology 146: 5063–5070, 2005.[CrossRef][Web of Science][Medline]
57. Van Dam EM, Robinson PJ. Ral: mediator of membrane trafficking. Int J Biochem Cell Biol 38: 1841–1847, 2006.[CrossRef][Web of Science][Medline]
58. Wang G, Wu WW, Zeng W, Chou CL, Shen RF. Label-free protein quantification using LC-coupled ion trap or FT mass spectrometry: reproducibility, linearity, and application with complex proteomes. J Proteome Res 5: 1214–1223, 2006.[CrossRef][Web of Science][Medline]
59. Yu MJ, Pisitkun T, Wang G, Shen RF, Knepper MA. LC-MS/MS analysis of apical and basolateral plasma membranes of rat renal collecting duct cells. Mol Cell Proteomics 5: 2131–2145, 2006.
60. Zheng B, Ma YC, Ostrom RS, Lavoie C, Gill GN, Insel PA, Huang XY, Farquhar MG. RGS-PX1, a GAP for G
s and sorting nexin in vesicular trafficking. Science 294: 1939–1942, 2001.
This article has been cited by other articles:
![]() |
X. Feng, H. Huang, Y. Yang, O. Frohlich, J. D. Klein, J. M. Sands, and G. Chen Caveolin-1 directly interacts with UT-A1 urea transporter: the role of caveolae/lipid rafts in UT-A1 regulation at the cell membrane Am J Physiol Renal Physiol, June 1, 2009; 296(6): F1514 - F1520. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. N. Sachs, T. Pisitkun, J. D. Hoffert, M.-J. Yu, and M. A. Knepper LC-MS/MS analysis of differential centrifugation fractions from native inner medullary collecting duct of rat Am J Physiol Renal Physiol, December 1, 2008; 295(6): F1799 - F1806. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |